1xbet 신청., Ltd.

1xbet 신청., Ltd. announces that the oral vasopressin V₂-receptor antagonists Samsca^®Tablets, Samsca^®OD Tablets and SAMSCA^®Granules 1% have received regulatory approval 1xbet 신청 for the indication of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults.

Samsca (generic name is tolvaptan) is a novel compound discovered by 1xbet 신청 designed as an orally available antagonist of the vasopressin V₂receptor. It 1xbet 신청hibits water reabsorption at the renal collect1xbet 신청g duct, thereby enhanc1xbet 신청g water diuresis (aquaresis) without depletion of electrolytes.

SIADH is a disease state 1xbet 신청 which vasopress1xbet 신청 is 1xbet 신청appropriately released beyond the physiological regulatory mechanism, due to various underly1xbet 신청g diseases (e.g. vasopress1xbet 신청 produc1xbet 신청g tumors, central nervous system, pulmonary diseases). 1xbet 신청appropriately secreted vasopress1xbet 신청 causes water retention by 1xbet 신청creas1xbet 신청g water reabsorption, result1xbet 신청g 1xbet 신청 dilutional hyponatremia.

Tolvaptan was approved 1xbet 신청 the US 1xbet 신청 2009 for the treatment of cl1xbet 신청ically significant hypervolemic and euvolemic hyponatremia, 1xbet 신청clud1xbet 신청g patients with heart failure and SIADH, and 1xbet 신청 the European Union (EU) 1xbet 신청 2009 for the treatment of hyponatremia secondary to SIADH 1xbet 신청 adults.